Results 141 to 150 of about 227,240 (251)

Logic‐Gated HSV‐TK/GCV Suicide Gene Circuit for Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
The BRAS comprises two modular genetic components driven by distinct tumor‐specific promoters and a failsafe layer with the NOT gate. This multi‐input logic gate circuit enables precise, specific expression of HSV‐TK in breast cancer cells with hardly expression in normal cell and effectively inhibits tumor growth in a triple‐negative breast cancer ...
Shasha Tang, Yuan Fang, Lingli Jin, Dongyang Liu, Yicheng Liu, Ruijia Zheng, Liyun Yong, Xin Wu, Longliang Qiao, Meiyan Wang, Fengfeng Cai   +10 more
wiley   +1 more source

Does the B7-H3 Immune Checkpoint Have High Potential as a Therapeutic Target? [PDF]

Cells
Agostini M, Traldi P, Hamdan M.
europepmc   +1 more source

Fibroblast Activation Protein Promotes Thoracic Aortic Dissection via PLAUR/ITGB1‐Mediated Pro‐inflammatory Macrophage Polarization

Advanced Science, EarlyView.
This study reveals that FAP promotes thoracic aortic dissection (TAD) through a nonenzymatic mechanism involving fibroblast‐macrophage crosstalk via the FAP/PLAUR/ITGB1/FAK axis. Targeting this pathway might offer a promising therapeutic strategy for TAD.
Hongqiao Zhu, Jianlie Wu, Ziyi Xu, Yifei Pei, Zaiping Jing, Jian Zhou, Rui Feng, Junjun Liu   +7 more
wiley   +1 more source

UBE2T‐Driven p53 Degradation Rewires Glycolysis to Orchestrate Lactylation‐Mediated CAFs Activation and ECM Deposition in Pancreatic Cancer

Advanced Science, EarlyView.
This study integrates multi‐omics to reveal the critical role of UBE2T in driving malignancy and stromal co‐evolution in PDAC. UBE2T potentiates glycolysis by regulating p53 degradation via a positive feedback loop, thereby promoting histone H3 lysine 18 lactylation in CAFs and stromal deposition. The UBE2T inhibitor PGG represents a potential strategy
Yong Ma, Wenbo Liu, Mingdou Li, Tao Wang, Bin Zhao, Keshen Wang, Qichen He, Haonan Sun, Huiguo Qing, Xiaoying Guan, Wengui Shi, Long Qin, Yuman Dong, Huinian Zhou, Zeyuan Yu, Xiangyan Jiang, Zuoyi Jiao   +16 more
wiley   +1 more source

Breaking Barriers: Immune Checkpoint Inhibitors in Breast Cancer. [PDF]

Pharmaceutics
Dmuchowski B, Hryniewicz WW, Barczak I, Fręśko K, Szarzyńska Z, Węclewski H, Ślężak JK, Dobosz P, Gryczka H.   +8 more
europepmc   +1 more source

Cuproptosis and Disulfidptosis Converge to Empower PD‐L1 Checkpoint Therapy via Cadict‐Induced PD‐L1 Translation

Advanced Science, EarlyView.
This study introduces Cadict, an EGFR‐targeted nanodrug that co‐delivers cuproptosis and disulfidptosis inducers to overcome immune resistance. Cadict synergistically enhances tumor cytotoxicity and sensitizes cancers to ICIs by upregulating PD‐L1 via an Eif5b‐dependent translation mechanism, fostering a potent antitumor immune response and ...
Shaoqing Huang, Shiyao Song, Xinhua Zhang, Jialing Gao, Ruihan Pu, Jiatong Dai, Xiaoxue Wu, Lulu Chen, Qinghai Li, Xiaoting Liu, Qi Zhou, Mei Song, Weiling He   +12 more
wiley   +1 more source

Upadacitinib for Immune Checkpoint Inhibitor-Related Dermatitis: A Nonrandomized Clinical Trial.

JAMA Oncol
Chen C, Liang X, Peng Z, Zou Y, He H, Zhang X, He Y, Wu S.   +7 more
europepmc   +1 more source

cDC1 Subtype‐Specific In Vivo Targeting of Liposomes

Advanced Science, EarlyView.
Dendritic cells, particularly the cDC1 subtype, offer a promising target for drug delivery via liposomes due to their pivotal role in immune regulation, allowing for amplified therapeutic responses. Herein, we show an integration of physicochemical characterization and cell experiments to achieve effective in vivo cDC1 targeting through anti‐CLEC9A ...
Maximilian Schaaf, Michael Fichter, Lin Jian, Felicia Schön, Carina Jung, Paul Schneider, Kai Speth, Ana Mateos‐Maroto, Volker Mailänder, Kaloian Koynov, Svenja Morsbach, Katharina Landfester   +11 more
wiley   +1 more source

Acetaminophen interactions with immune checkpoint inhibitors: guilt by association? [PDF]

J Immunother Cancer
de Lemos ML, de Lemos J, Kletas V, Latt R, Mucovic J.   +4 more
europepmc   +1 more source

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

Advanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong, Yuhang Xie, Zhijie Weng, Yongzhi Wu, Longjiang Li, Bo Li   +5 more
wiley   +1 more source